{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:56:33Z","timestamp":1762458993965},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1007\/s12185-012-1015-z","type":"journal-article","created":{"date-parts":[[2012,2,7]],"date-time":"2012-02-07T06:03:46Z","timestamp":1328594626000},"page":"119-124","source":"Crossref","is-referenced-by-count":14,"title":["Endothelial progenitor cell-based therapy for hemophilia A"],"prefix":"10.1007","volume":"95","author":[{"given":"Hideto","family":"Matsui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,2,8]]},"reference":[{"key":"1015_CR1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1056\/NEJM199401063300108","volume":"330","author":"LW Hoyer","year":"1994","unstructured":"Hoyer LW. Hemophilia A. N Engl J Med. 1994;330:38\u201347.","journal-title":"N Engl J Med"},{"key":"1015_CR2","first-page":"97","volume-title":"Hemostasis and Thrombosis: basic principles and clinical practice","author":"PH Levine","year":"1987","unstructured":"Levine PH. Clinical manifestation and therapy of hemophilias A and B. In: Coloman RW, Hirsh J, Marder VJ, Salzman EW, editors. Hemostasis and Thrombosis: basic principles and clinical practice. Philadelphia: Lippincott, J.B; 1987. p. 97\u2013111."},{"key":"1015_CR3","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0140-6736(03)13405-8","volume":"361","author":"PH Boloton-Maggs","year":"2003","unstructured":"Boloton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet. 2003;361:1801\u20139.","journal-title":"Lancet"},{"key":"1015_CR4","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1046\/j.1365-2516.2003.00840.x","volume":"10","author":"LA Valentino","year":"2004","unstructured":"Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous access devices in hemophilia. Haemophilia. 2004;10:134\u201346.","journal-title":"Haemophilia"},{"key":"1015_CR5","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1365-2516.2004.00901.x","volume":"10","author":"M Brooker","year":"2004","unstructured":"Brooker M. The World Federation of Hemophilia\u2019s third global forum on the Safety and Supply of Hemophilia Treatment Products, 22\u201323 September 2003, Budapest, Hungary. Haemophilia. 2004;10:290\u20134.","journal-title":"Haemophilia."},{"key":"1015_CR6","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1046\/j.1351-8216.2003.00831.x","volume":"9","author":"P Jones","year":"2003","unstructured":"Jones P, Robillard L. The World Federation of Hemophilia: 40\u00a0years of improving hemophilia care worldwide. Haemophilia. 2003;9:663\u20139.","journal-title":"Haemophilia"},{"issue":"Suppl 4","key":"1015_CR7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2516.2004.00998.x","volume":"10","author":"VS Blanchette","year":"2004","unstructured":"Blanchette VS, Manco-Johnson M, Santagostino E, Ljung R. Optimizing factor prophylaxis for the hemophilia population: where do we stand? Haemophilia. 2004;10(Suppl 4):97\u2013104.","journal-title":"Haemophilia"},{"key":"1015_CR8","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","volume":"344","author":"PM Mannucci","year":"2001","unstructured":"Mannucci PM, Tuddenham EG. The hemophilias\u2014from royal genes to gene therapy. N Engl J Med. 2001;344:1773\u20139.","journal-title":"N Engl J Med"},{"key":"1015_CR9","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1182\/blood.V60.3.727.727","volume":"60","author":"AR Giles","year":"1982","unstructured":"Giles AR, Tinlin S, Greenwood R. A canine model of hemophilic (factor VIII:C deficiency) bleeding. Blood. 1982;60:727.","journal-title":"Blood"},{"key":"1015_CR10","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1055\/s-0037-1613063","volume":"87","author":"C Hough","year":"2002","unstructured":"Hough C, Kamisue S, Cameron C, et al. Aberrant splicing and premature termination of transcription of the FVIII gene as a cause of severe hemophilia A: similarities with the intron 22 inversion mutation in human hemophilia. Thromb Haemost. 2002;87:659\u201365.","journal-title":"Thromb Haemost"},{"key":"1015_CR11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1055\/s-0037-1614984","volume":"79","author":"C Cameron","year":"1998","unstructured":"Cameron C, Notley C, Hoyle S, et al. The canine factor VIII cDNA and 5\u2032 flanking sequence. Thromb Haemost. 1998;79:317\u201322.","journal-title":"Thromb Haemost"},{"key":"1015_CR12","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1089\/10430340260201671","volume":"13","author":"C Notley","year":"2002","unstructured":"Notley C, Kiloran A, Cameron C, Wynd K, Hough C, Lillicrap D. The canine FVIII 3\u2032-untranslated region and a concatemeric hepatocyte nuclear factor 1 regulatory element enhance factor VIII transgene expression in vivo. Hum Gene Ther. 2002;13:1583\u201393.","journal-title":"Hum Gene Ther"},{"key":"1015_CR13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1055\/s-2004-825634","volume":"30","author":"FE Rawle","year":"2004","unstructured":"Rawle FE, Lillicrap D. Preclinical animal models for hemophilia gene therapy: predictive value and limitations. Semin Thromb Haemost. 2004;30:205\u201313.","journal-title":"Semin Thromb Haemost"},{"key":"1015_CR14","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1182\/blood-2003-05-1426","volume":"103","author":"BD Brown","year":"2004","unstructured":"Brown BD, Shi CX, Powell S, Hurlbut D, Graham FL, Lillicrap D. Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A. Blood. 2004;103:804\u201310.","journal-title":"Blood"},{"key":"1015_CR15","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/nm900","volume":"9","author":"H Chao","year":"2003","unstructured":"Chao H, Mansfield SG, Bartel RC, et al. Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing. Nat Med. 2003;9:1015\u20139.","journal-title":"Nat Med"},{"key":"1015_CR16","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1182\/blood-2002-03-0823","volume":"101","author":"MK Chuah","year":"2003","unstructured":"Chuah MK, Schiedner G, Thorrez L, et al. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors. Blood. 2003;101:1734\u201343.","journal-title":"Blood"},{"key":"1015_CR17","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1182\/blood.V91.9.3273","volume":"91","author":"S Connelly","year":"1998","unstructured":"Connelly S, Andrews JL, Gallo AM, et al. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood. 1998;91:3273\u201381.","journal-title":"Blood"},{"key":"1015_CR18","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1073\/pnas.92.4.1023","volume":"92","author":"VJ Dwarki","year":"1995","unstructured":"Dwarki VJ, Belloni P, Nijjar T, et al. Gene therapy for hemophilia A: production of therapeutic levels of human factor VIII in vivo in mice. Proc Natl Acad Sci USA. 1995;92:1023\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1015_CR19","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1089\/10430349950017473","volume":"10","author":"AM Gallo-Penn","year":"1999","unstructured":"Gallo-Penn AM, Shirley PS, Andrew JL, et al. In vivo evaluation of an adenoviral vector encoding canine factor VIII: high-level, sustained expression in hemophilia mice. Hum Gene Ther. 1999;10:1791\u2013802.","journal-title":"Hum Gene Ther"},{"key":"1015_CR20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1126\/science.8211118","volume":"262","author":"MA Kay","year":"1993","unstructured":"Kay MA, Rorhenberg S, Landen CN, et al. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. Science. 1993;262:117\u20139.","journal-title":"Science"},{"key":"1015_CR21","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1182\/blood-2003-08-2954","volume":"103","author":"R Sarkar","year":"2004","unstructured":"Sarkar R, Tetreault R, Gao G, et al. Total correction of hemophilia a mice with canine FVIII using an AAV 8 serotype. Blood. 2004;103:1253\u201360.","journal-title":"Blood"},{"key":"1015_CR22","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood-2003-01-0292","volume":"102","author":"CD Scallan","year":"2003","unstructured":"Scallan CD, Lillicrap D, Jiang H, et al. Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector. Blood. 2003;102:2031\u20137.","journal-title":"Blood"},{"key":"1015_CR23","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood-2009-03-202267","volume":"114","author":"H Matsui","year":"2009","unstructured":"Matsui H, Shibata M, Brown B, et al. A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3+ T regulatory cells. Blood. 2009;114:677\u201385.","journal-title":"Blood"},{"key":"1015_CR24","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/mt.2010.290","volume":"19","author":"H Matsui","year":"2011","unstructured":"Matsui H, Hegadorn C, Ozelo M, et al. A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of hemophilia A. Mol Ther. 2011;19:723\u201330.","journal-title":"Mol Ther"},{"key":"1015_CR25","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJM200106073442301","volume":"344","author":"DA Roth","year":"2001","unstructured":"Roth DA, Tawa NE Jr, O\u2019Brien JM, Treco DA, Selden RF. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med. 2001;344:1735\u201342.","journal-title":"N Engl J Med"},{"key":"1015_CR26","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2003-01-0167","volume":"102","author":"JS Powell","year":"2003","unstructured":"Powell JS, Ragni MV, White GC, et al. Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administrated by peripheral intravenous infusion. Blood. 2003;102:2038\u201345.","journal-title":"Blood"},{"key":"1015_CR27","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1182\/blood-2002-10-3296","volume":"101","author":"CS Manno","year":"2003","unstructured":"Manno CS, Chew AJ, Hutchinson S, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood. 2003;101:2963\u201372.","journal-title":"Blood"},{"key":"1015_CR28","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1182\/blood-2001-11-0067","volume":"100","author":"BD Brown","year":"2002","unstructured":"Brown BD, Lillicrap D. Dangerous liaisons: the role of \u201cdanger\u201d signals in the immune response to gene therapy. Blood. 2002;100:1133\u201340.","journal-title":"Blood"},{"key":"1015_CR29","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.304.5676.1423b","volume":"304","author":"J Kaiser","year":"2004","unstructured":"Kaiser J. Gene therapy. Side effects sideline hemophilia trial. Science. 2004;304:1423\u20135.","journal-title":"Science"},{"key":"1015_CR30","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","volume":"302","author":"S Hacein-Bey-Abina","year":"2003","unstructured":"Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302:415\u20139.","journal-title":"Science"},{"key":"1015_CR31","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1634\/stemcells.2006-0699","volume":"25","author":"H Matsui","year":"2007","unstructured":"Matsui H, Shibata M, Brown B, et al. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors. Stem Cells. 2007;25:2660\u20139.","journal-title":"Stem Cells"},{"key":"1015_CR32","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1172\/JCI8071","volume":"105","author":"Y Lin","year":"2000","unstructured":"Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest. 2000;105:71\u20137.","journal-title":"J Clin Invest"},{"key":"1015_CR33","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood.V87.6.2292.bloodjournal8762292","volume":"87","author":"SJ Koppelman","year":"1996","unstructured":"Koppelman SJ, van Hoeij M, Vink T, et al. Requirements of von Willebrand factor to protect factor VIII inactivation by activated protein C. Blood. 1996;87:2292\u2013300.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-012-1015-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-012-1015-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-012-1015-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T20:11:12Z","timestamp":1593634272000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-012-1015-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["1015"],"URL":"https:\/\/doi.org\/10.1007\/s12185-012-1015-z","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}